tbuckley/cabot-search huggingface dataset:
Phase II Trial of Chemoradiotherapy Concurrent with S-1 Plus Cisplatin in Patients with Unresectable Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN): Results of the Japan Clinical Oncology Group Study, JCOG 0706
Authors: M. Fujii, M. Tahara, N. Kiyota, J. Mizusawa, K. Nakamura, R. Hayashi, T. Akimoto, Y. Hasegawa, S. Iwae, N. Monden, K. Matsuura, H. Fujii, Y. Onozawa, A. Homma, A. Kubota
Journal: Annals of Oncology (2012)
Specificity, kinetics and longevity of antibody responses to avian influenza A(H7N9) virus infection in humans
Authors: Junbo Chen, Huachen Zhu, Peter W. Horby, Qianli Wang, Jiaxin Zhou, Hui Jiang, Liwei Liu, Tianchen Zhang, Yongli Zhang, Xinhua Chen, Xiaowei Deng, Birgit Nikolay, Wei Wang, Simon Cauchemez, Yi Guan, Timothy M. Uyeki, Hongjie Yu
Journal: Journal of Infection (2020)

The long-term dynamics of antibody responses in patients with influenza A(H7N9) virus infection are not well understood.We conducted a longitudinal serological follow-up study in patients who were hospitalized with A(H7N9) virus infection, during 2013-2018. A(H7N9) virus-specific antibody responses were assessed by hemagglutination inhibition (HAI) and neutralization (NT) assays. A random intercept model was used to fit a curve to HAI antibody responses over time. HAI antibody responses were compared by clinical severity.Of 67 patients with A(H7N9) virus infection, HAI antibody titers reached 40 on average 11 days after illness onset and peaked at a titer of 290 after three months, and average titers of ≥80 and ≥40 were present until 11 months and 22 months respectively. HAI antibody responses were significantly higher in patients who experienced severe disease, including respiratory failure and acute respiratory distress syndrome, compared with patients who experienced less severe illness.Patients with A(H7N9) virus infection who survived severe disease mounted higher antibody responses that persisted for longer periods compared with those that experienced moderate disease. Studies of convalescent plasma treatment for A(H7N9) patients should consider collection of donor plasma from survivors of severe disease between 1 and 11 months after illness onset.
A heavy metal baseline score predicts outcome in acute myeloid leukemia
Authors: Maro Ohanian, Philippe Telouk, Steven Kornblau, Francis Albarede, Peter Ruvolo, Rebecca S. S. Tidwell, Adriana Plesa, Rashmi Kanagal‐Shamanna, Eva‐Laure Matera, Jorge Cortes, Arch Carson, Charles Dumontet
Journal: American Journal of Hematology (2020)

Despite abundant epidemiological data linking metals to leukemia and other cancers, baseline values of toxic and essential metals in patients with leukemia and the clinical impact of these metals remain unknown. Thus, we sought to quantify metal values in untreated patients with acute myeloid leukemia (AML) and controls and determine the impact of metal values on AML patients' survival. Serum samples from patients with untreated AML and controls at Hospices Civils de Lyon were analyzed and compared for trace metals and copper isotopic abundance ratios with inductively coupled plasma mass spectrometry. Survival analysis was performed as a function of metal values, and a multi-metal score was developed for patients with AML. Serum samples were collected from 67 patients with untreated AML and 94 controls. Most patients had intermediate-risk cytogenetics (63.1%) without FLT3 internal tandem duplication mutations (75.6%) or NPM1 mutations (68.1%). Most metal values differed significantly between AML and control groups. Patients with lower magnesium and higher cadmium values had the worst survival rates, with only 36% surviving at 6 months (P = .001). The adverse prognostic effect of this combination was maintained on multivariate analysis. Based on this, we developed a novel metal score, which accounts for multiple relative abnormalities in the values of five toxic and five essential metals. Patients with a higher metal score had significantly worse survival, which was maintained on multivariate analysis (P = .03). This baseline metal scoring system was also prognostic when we applied it to a separate population of front-line AML patients.
The Merck Manual of Diagnosis and Therapy
Authors: F. D. Gray
Journal: JAMA (1982)

This venerable manual is a quick source of practical information about the gamut of disease processes and preventive medicine. The book is so well known that probably only first-year students would need an introduction. There are other quick reference manuals of general medicine, but the experience and prestige that the<i>Merck Manual</i>has acquired since the first edition in 1899 have made it the dominant publication in its field. The manual has proved its value for everybody in the health sciences, and it is also used as a standard reference for members of the press, the legal profession, clergymen—in fact by nearly everyone who has an interest in health. The first copy I owned was the sixth edition, which I bought secondhand, thereby gaining the annotations of the previous owner. It could easily be slipped into my pocket and was my first line of defense as a clinical clerk. In
What Factors Affect Long-Term Survival After Responding to Gefitinib in Advanced Non-Small-Cell Lung Cancer? Real World Evidence
Authors: R. Takahashi, F. Imamura, S. Morita, M. Mori, K. Komuta, T. Kijima, Y. Namba, K. Nishino, S. Yamamoto, H. Hirata, I. Tachibana, A. Kumanogoh
Journal: Annals of Oncology (2012)
Impact of Soluble Tumor Necrosis Factor-Receptors (STNF-RS) Shedding on Outcome in PAtients Treated With Ngr-Htnf
Authors: P.A. Zucali, M. Simonelli, F. De Vincenzo, E. Lorenzi, A. Santoro, A. Lambiase, C. Bordignon
Journal: Annals of Oncology (2012)
Transcription factor c-Maf is a checkpoint that programs macrophages in lung cancer
Authors: Min Liu, Zan Tong, Chuanlin Ding, Fengling Luo, Shouzhen Wu, Caijun Wu, Sabrin Albeituni, Liqing He, Xiaoling Hu, David Tieri, Eric C. Rouchka, Michito Hamada, Satoru Takahashi, Andrew A. Gibb, Goetz Kloecker, Huang-ge Zhang, Michael Bousamra, Bradford G. Hill, Xiang Zhang, Jun Yan
Journal: Journal of Clinical Investigation (2020)

Macrophages have been linked to tumor initiation, progression, metastasis, and treatment resistance. However, the transcriptional regulation of macrophages driving the protumor function remains elusive. Here, we demonstrate that the transcription factor c-Maf is a critical controller for immunosuppressive macrophage polarization and function in cancer. c-Maf controls many M2-related genes and has direct binding sites within a conserved noncoding sequence of the Csf-1r gene and promotes M2-like macrophage–mediated T cell suppression and tumor progression. c-Maf also serves as a metabolic checkpoint regulating the TCA cycle and UDP-GlcNAc biosynthesis, thus promoting M2-like macrophage polarization and activation. Additionally, c-Maf is highly expressed in tumor-associated macrophages (TAMs) and regulates TAM immunosuppressive function. Deletion of c-Maf specifically in myeloid cells results in reduced tumor burden with enhanced antitumor T cell immunity. Inhibition of c-Maf partly overcomes resistance to anti–PD-1 therapy in a subcutaneous LLC tumor model. Similarly, c-Maf is expressed in human M2 and tumor-infiltrating macrophages/monocytes as well as circulating monocytes of human non–small cell lung carcinoma (NSCLC) patients and critically regulates their immunosuppressive activity. The natural compound β-glucan downregulates c-Maf expression on macrophages, leading to enhanced antitumor immunity in mice. These findings establish a paradigm for immunosuppressive macrophage polarization and transcriptional regulation by c-Maf and suggest that c-Maf is a potential target for effective tumor immunotherapy.
Epigenetic Silencing of CDR1as Drives IGF2BP3-Mediated Melanoma Invasion and Metastasis
Authors: Douglas Hanniford, Alejandro Ulloa-Morales, Alcida Karz, Maria Gabriela Berzoti-Coelho, Rana S. Moubarak, Beatriz Sánchez-Sendra, Andreas Kloetgen, Veronica Davalos, Jochen Imig, Pamela Wu, Varshini Vasudevaraja, Diana Argibay, Karin Lilja, Tommaso Tabaglio, Carlos Monteagudo, Ernesto Guccione, Aristotelis Tsirigos, Iman Osman, Iannis Aifantis, Eva Hernando
Journal: Cancer Cell (2020)
Nonphagocytic Activation of NOX2 Is Implicated in Progressive Nonalcoholic Steatohepatitis During Aging
Authors: Joy X. Jiang, Sarah R. Fish, Alexey Tomilov, Yuan Li, Weiguo Fan, Ali Dehnad, David Gae, Suvarthi Das, Gergely Mozes, Gregory W. Charville, Jon Ramsey, Gino Cortopassi, Natalie J. Török
Journal: Hepatology (2020)

Background and Aims Older patients with obesity/type II diabetes mellitus frequently present with advanced NASH. Whether this is due to specific molecular pathways that accelerate fibrosis during aging is unknown. Activation of the Src homology 2 domain–containing collagen‐related (Shc) proteins and redox stress have been recognized in aging; however, their link to NASH has not been explored. Approach and Results Shc expression increased in livers of older patients with NASH, as assessed by real time quantitative PCR (RT‐qPCR) or western blots. Fibrosis, Shc expression, markers of senescence, and nicotinamide adenine dinucleotide phosphate, reduced form oxidases (NOXs) were studied in young/old mice on fast food diet (FFD). To inhibit Shc in old mice, lentiviral (LV)–short hairpin Shc versus control‐LV were used during FFD. For hepatocyte‐specific effects, floxed ( fl /fl ) Shc mice on FFD were injected with adeno‐associated virus 8–thyroxine‐binding globulin–Cre‐recombinase versus control. Fibrosis was accelerated in older mice on FFD, and Shc inhibition by LV in older mice or hepatocyte‐specific deletion resulted in significantly improved inflammation, reduction in senescence markers in older mice, lipid peroxidation, and fibrosis. To study NOX2 activation, the interaction of p47 phox (NOX2 regulatory subunit) and p52Shc was evaluated by proximity ligation and coimmunoprecipitations. Palmitate‐induced p52Shc binding to p47 phox , activating the NOX2 complex, more so at an older age. Kinetics of binding were assessed in Src homology 2 domain (SH2) or phosphotyrosine‐binding (PTB) domain deletion mutants by biolayer interferometry, revealing the role of SH2 and the PTB domains. Lastly, an in silico model of p52Shc/p47 phox interaction using RosettaDock was generated. Conclusions Accelerated fibrosis in the aged is modulated by p52Shc/NOX2. We show a pathway for direct activation of the phagocytic NOX2 in hepatocytes by p52Shc binding and activating the p47 phox subunit that results in redox stress and accelerated fibrosis in the aged.
Topical Application of TJ-14 (Hangeshashinto) in the Treatment of Chemotherapy-Induced Oral Mucositis: A Radomized, Placebo-Controlled, Double-Blind, Phase II Trial
Authors: N. Nagata, C. Matsuda, Y. Munemoto, M. Oshiro, M. Kataoka, Y. Shindo, S. Morita, T. Kono, J. Sakamoto, H. Mishima
Journal: Annals of Oncology (2012)
Targeting PD-1 or PD-L1 in Metastatic Kidney Cancer: Combination Therapy in the First-Line Setting
Authors: David H. Aggen, Charles G. Drake, Brian I. Rini
Journal: Clinical Cancer Research (2020)

Recent FDA approvals of regimens targeting programmed death 1 (PD-1) in combination with anti-CTLA-4 or with VEGF tyrosine kinase inhibitors are reshaping front-line therapy for metastatic kidney cancer. In parallel, therapeutics specific for programmed death ligand 1 (PD-L1), one of the two major ligands for PD-1, are under continued investigation. Surprisingly, not all PD-1 and PD-L1 agents lead to similar clinical outcomes, potentially due to biological differences in the cellular expression and regulation of these targets. Here, we review current clinical data on combination immune checkpoint inhibitor therapy in metastatic kidney cancer and discuss the relevant biology of PD-1 and PD-L1. The design of future rational combination therapy trials in metastatic renal cell carcinoma will rely upon an understanding of this biology, along with an evolving understanding of immune cell populations and their functional states in the tumor microenvironment.
Multitrait analysis of glaucoma identifies new risk loci and enables polygenic prediction of disease susceptibility and progression
Authors: Jamie E. Craig, Xikun Han, Ayub Qassim, Mark Hassall, Jessica N. Cooke Bailey, Tyler G. Kinzy, Anthony P. Khawaja, Jiyuan An, Henry Marshall, Puya Gharahkhani, Robert P. Igo, Stuart L. Graham, Paul R. Healey, Jue-Sheng Ong, Tiger Zhou, Owen Siggs, Matthew H. Law, Emmanuelle Souzeau, Bronwyn Ridge, Pirro G. Hysi, Kathryn P. Burdon, Richard A. Mills, John Landers, Jonathan B. Ruddle, Ashish Agar, Anna Galanopoulos, Andrew J. R. White, Colin E. Willoughby, Nicholas H. Andrew, Stephen Best, Andrea L. Vincent, Ivan Goldberg, Graham Radford-Smith, Nicholas G. Martin, Grant W. Montgomery, Veronique Vitart, Rene Hoehn, Robert Wojciechowski, Jost B. Jonas, Tin Aung, Louis R. Pasquale, Angela Jane Cree, Sobha Sivaprasad, Neeru A. Vallabh, Ananth C. Viswanathan, Francesca Pasutto, Jonathan L. Haines, Caroline C. W. Klaver, Cornelia M. van Duijn, Robert J. Casson, Paul J. Foster, Peng Tee Khaw, Christopher J. Hammond, David A. Mackey, Paul Mitchell, Andrew J. Lotery, Janey L. Wiggs, Alex W. Hewitt, Stuart MacGregor
Journal: Nature Genetics (2020)
The International Society for Children’s Health and the Environment Commits to Reduce Its Carbon Footprint to Safeguard Children’s Health
Authors: Brenda Eskenazi, Ruth A. Etzel, Kam Sripada, Maryann R. Cairns, Irva Hertz-Picciotto, Katarzyna Kordas, João Paulo Machado Torres, Howard W. Mielke, Youssef Oulhote, Lesliam Quirós-Alcalá, José R. Suárez-López, Marya G. Zlatnik
Journal: Environmental Health Perspectives (2020)

The Lancet Countdown and the 2018 Intergovernmental Panel on Climate Change declared that the worst impacts of climate change are and will continue to be felt disproportionately by children. Children are uniquely vulnerable to the consequences of climate change, including heat stress, food scarcity, increases in pollution and vector-borne diseases, lost family income, displacement, and the trauma of living through a climate-related disaster. These stressors can result in long-lasting physical and mental health sequelae. Based upon these concerns associated with climate change, the International Society for Children's Health and the Environment developed a statement about ways in which the Society could take action to reduce its contribution of greenhouse gas emissions. The objective of this article is to report our Society's plans in hopes that we may stimulate other scientific societies to take action. https://doi.org/10.1289/EHP6578
Individualized Asparaginase Dosing in Childhood Acute Lymphoblastic Leukemia
Authors: Robin Q.H. Kloos, Rob Pieters, Florine M.V. Jumelet, Hester A. de Groot-Kruseman, Cor van den Bos, Inge M. van der Sluis
Journal: Journal of Clinical Oncology (2020)

PURPOSE In the DCOG ALL-11 protocol, polyethylene glycol–conjugated Escherichia coli asparaginase (PEGasparaginase) and Erwinia asparaginase treatment of pediatric acute lymphoblastic leukemia are individualized with therapeutic drug monitoring (TDM). The efficacy of TDM and its effect on asparaginase-associated toxicity are reported. PATIENTS AND METHODS After induction with 3 fixed intravenous doses of 1,500 IU/m 2 PEGasparaginase, medium-risk patients (n = 243) received 14 individualized doses that targeted trough levels of 100-250 IU/L, standard-risk patients (n = 108) received 1 individualized dose, and high-risk patients (n = 18) received 2-5 fixed administrations (1,500 IU/m 2 ). After a neutralizing hypersensitivity reaction, patients were started with 20,000 IU/m 2 Erwinia asparaginase 3 times per week, and l-asparagine was measured to monitor asparaginase efficacy. Several asparaginase-associated toxicities were studied. RESULTS The final median PEGasparaginase dose was lowered to 450 IU/m 2 . Overall, 97% of all trough levels of nonallergic patients were &gt; 100 IU/L. Asparagine was &lt; 0.5 μM in 96% and 67% of the PEGasparaginase and Erwinia asparaginase levels &gt; 100 IU/L, respectively. Ten percent developed a neutralizing hypersensitivity reaction to PEGasparaginase, of which 40% were silent inactivations. The cumulative incidence of grade 3-4 pancreatitis, central neurotoxicity, and thromboses was 12%, 4%, and 6%, respectively, and not associated with asparaginase activity levels. During medium-risk intensification, 50% had increased ALT and 3% hyperbilirubinemia (both grade 3/4 and correlated with asparaginase activity levels), and 37% had grade 3/4 hypertriglyceridemia. Hypertriglyceridemia occurred less in intensification compared with ALL-10 (37% v 47%), which is similar to ALL-11 but with higher asparaginase levels during intensification. CONCLUSION TDM of asparaginase results in a significant reduction of the PEGasparaginase dose with adequate asparaginase activity levels and sufficient asparagine depletion. In addition, with TDM, silent inactivation and allergic-like reactions were identified. However, the effect of reduced asparaginase activity levels on toxicity is limited.
Preliminary Result of a Multicenter Phase II Study of Chemoradiotherapy with Docetaxel for Elderly Patients with Stage II/III Esophageal Carcinoma
Authors: C. Katada, J. Hashimoto, N. Kotani, K. Kato, Y. Ito, N. Hokamura, H. Ishiyama, Y. Tamaki, T. Nakamura, T. Ura, D. Takahari, S. Yamamoto, K. Nagai
Journal: Annals of Oncology (2012)
Relationship Between EGFR Expression Level, EGFR Mutation Status and the Efficacy of Chemotherapy Plus Cetuximab in Flex Study Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Authors: J. Douillard, R. Pirker, K.J. O'Byrne, K.M. Kerr, S. Störkel, I. Celik, A. von Heydebreck, F.A. Shepherd
Journal: Annals of Oncology (2012)
Let's call a memory a memory, but what kind?
Authors: Nazim Keven
Journal: Behavioral and Brain Sciences (2019)

Abstract Hoerl &amp; McCormack argue that animals cannot represent past situations and subsume animals’ memory-like representations within a model of the world. I suggest calling these memory-like representations as what they are without beating around the bush. I refer to them as event memories and explain how they are different from episodic memory and how they can guide action in animal cognition.
Corrigendum to “Depletion of NAD pool contributes to impairment of endothelial progenitor cell mobilization in diabetes” [Metab Clin Exp 65 (2016) 852–862]
Authors: Pei Wang, Xi Yang, Zheng Zhang, Jie Song, Yun-Feng Guan, Da-Jin Zou, Chao-Yu Miao
Journal: Metabolism (2020)
Abstract 10512: When a Child Becomes Terminal: Discrepant Adolescent and Parent Perspectives on Discussing a Terminal Prognosis With Adolescents With Cardiomyopathy, Heart Failure, and Heart Transplant
Authors: Katherine Hansen, Lindsay A Edwards, Roger Luong, Kifle Yohannes, Bonnie Halpern-Felsher, Harvey Cohen, Beth Kaufman
Journal: Circulation (2018)

Introduction: Adolescents with cardiomyopathy, heart failure, and heart transplant (CMHF/HTx) are at risk of life-changing complications and premature death. The importance of advance care planning...
P-0100 H4K12 And H3K18 Acetylation Associates with poor Prognosis in Pancreatic Cancer
Authors: Patricia Izetti, Camila Juliano, Marcia Pereira, Alex dos Santos, Charles Pedro Cerveira, Ana Lucia Abujamra, Patricia Ashton-Prolla, Alessandro Osvaldt, Maria Isabel Edelweiss
Journal: Annals of Oncology (2012)
Amphiregulin and Epiregulin Polymorphisms as Pharmacogenetic Predictive Factors for Response to Irinotecan Plus Anti-Egfr Treatment
Authors: A. Sebio Garcia, D. Páez, J. Salazar Blanco, M. Tobeña Puyal, M. Martín-Richard, A. Barnadas, M. Baiget
Journal: Annals of Oncology (2012)
c-MYC Expression is Modulated by Statins Use and it's Correlated with Time to Progression (TTP) in Men with Localised Prostate Cancer Treated with Radical Radiotherapy
Authors: D. Torrejon Castro, I. De Torres, G. Sánchez-Ollé, X. Maldonado, R. Morales-Barrera, C. Suarez, C. Valverde Morales, I. Nunez Hernandez, J. Morote, J. Carles
Journal: Annals of Oncology (2012)
Thyroid hormone inhibits hepatocellular carcinoma progression via induction of differentiation and metabolic reprogramming
Authors: Marta Anna Kowalik, Elisabetta Puliga, Lavinia Cabras, Pia Sulas, Annalisa Petrelli, Andrea Perra, Giovanna Maria Ledda-Columbano, Andrea Morandi, Simone Merlin, Claudia Orrù, Carlos Sanchez-Martin, Francesca Fornari, Laura Gramantieri, Matteo Parri, Andrea Rasola, Sara Erika Bellomo, Carlos Sebastian, Antonia Follenzi, Silvia Giordano, Amedeo Columbano
Journal: Journal of Hepatology (2020)
The Feasibility Study of CDDP Plus Docetaxel Followed by TS-1 Maintenance as Post Operative Adjuvant Chemotherapy for Completely Resected Pathological Stage II to IIIA NSCLC Patient
Authors: H. Sakai, K. Suzuki, S. Niho, N. Ikeda, T. Kaburagi, T. Koike, K. Minato, T. Kato, H. Okamoto, T. Seto, Y. Hosomi, M. Tsuboi, K. Watanabe, M. Takeuchi
Journal: Annals of Oncology (2012)
Unsettling beauty: RCP show challenges “neutrality of medical gaze”
Authors: Tom Moberly
Journal: BMJ (2020)

Contemporary ceramics feature alongside illustrated dissections from the 18th and 19th centuries in an exhibition at the Royal College of Physicians in London. “Under the skin: anatomy, art and identity” sets out to explore “the unsettling beauty of the human body from the medieval age to the contemporary world.”

The show includes works from a …
Docetaxel Regimen as Second-Line Treatment for Pretreated Advanced NSCLC Patients - A Large-Scale, Multicenter, Uncontrolled, Registry Study in China
Authors: S. Lu, Y.L. Wu, Y.Z. Wang, X. Song, L.Q. Jia, G.Y. Chen, T. Sun, K.H. Lu, M. Ouyang, H. Zhao
Journal: Annals of Oncology (2012)
Evaluation of Aromatase Inhibitor-Related Arthralgia in Early Breast Cancer Patients
Authors: N. Romero Laorden, C. Olier, X. Mielgo, S. Falagán, A. Velástegui, S. Hernando, J.C. Cámara, A. Hurtado, J. Garcia-Donas, C. Jara
Journal: Annals of Oncology (2012)
Thrombin contributes to cancer immune evasion via proteolysis of platelet-bound GARP to activate LTGF-β
Authors: Alessandra Metelli, Bill X. Wu, Brian Riesenberg, Silvia Guglietta, John D. Huck, Catherine Mills, Anqi Li, Saleh Rachidi, Carsten Krieg, Mark P. Rubinstein, Daniel T. Gewirth, Shaoli Sun, Michael B. Lilly, Amy H. Wahlquist, David P. Carbone, Yiping Yang, Bei Liu, Zihai Li
Journal: Science Translational Medicine (2020)

Proteolysis of platelet-bound GARP by thrombin liberates active TGF-β and contributes to cancer immune evasion in the tumor microenvironment.
Multicenter Institutional Experience of Surgically Resected Thymic Epithelial Tumors (TETS): an Observational Report on Behalf of F.O.N.I.C.A.P. (Forza Operativa Nazionale Interdisciplinare Contro Il Cancro Del Polmone)
Authors: G. Genestreti, M.A. Burgio, L. Ampollini, S. Sanna, M. Monti, A. Santo, M. Mezzetti, G. Gavelli, A. Verlicchi, R. Buosi
Journal: Annals of Oncology (2012)